Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Resverlogix Corp. has announced that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208, Resverlogix’s oral small molecule therapy for the treatment of atherosclerosis, in patients with stable coronary artery disease (CAD). The Cleveland Clinic has named this trial, ASSERT, which stands for ApoA1 Synthesis Stimulation Evaluation in Patients Requiring Treatment for Coronary Artery Disease.
For the full story, Click Here
- Cardiovascular Systems Introduces First Patient in CALCIUM 360degree Clinical Trial
- MIV Therapeutics provides VESTASYNC I trial’s update
- MGuard coronary stent trial depicts positive efficacy and safety data
- Sutureless Connector intrathecal catheter recalled
